Laser prophylaxis for age-related macular degeneration

Canadian Journal of Ophthalmology

Volumn 40, Issue 3, 2005, Pages 320-331

  Hsu, Jason ^a   Maguire, Maureen G ^a   Fine, Stuart L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Age factor; Choroidal neovascularization; Drusen; Laser photocoagulation; Macular degeneration

Indexed keywords

COLLAGEN; ELASTIN; LIPID; PHOSPHOLIPID;

ARGON LASER; BIOMICROSCOPY; BRUCH MEMBRANE; CLINICAL TRIAL; CONTRAST SENSITIVITY; DRUSEN; FLUORESCENCE ANGIOGRAPHY; HUMAN; INCIDENCE; LASER COAGULATION; PHOTORECEPTOR; PIGMENT EPITHELIUM; RETINA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK; SCAR; SUBRETINAL NEOVASCULARIZATION; THEORY; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT;

EID: 21744444909     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(05)80075-4     Document Type: Article

References (68)

1. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85.
2. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study or cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980;24:335-610.
3. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;14:1412-7.
4. Klein R, Klein BE, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:933-45.
5. Sorsby A. The incidence and causes of blindness in England and Wales, 1948-1962. Reports on public health and medical subjects, no. 114. London: Her Majesty's Stationery Office; 1966.
6. National Eye Institute. Age-related macular degeneration: status of research. Report to Congress. Bethesda, Md.: National Eye Institute, National Institutes of Health, US Department of Health and Human Services; 1997.
7. Ferris FL. Senile macular degeneration: review of epidemiologic features. Am J Ophthalmol 1983;118:132-51.
8. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
9. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy after five years. Results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-14.
10. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109:1242-57.
11. Macular Photocoagulation Study Group. Laser photocoagulation for subfoveal neovascular lesions or age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200-9.
12. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500-9.
13. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report no. 1 [published erratum appears in Arch Ophthalmol 2000; 118: 488]. Arch Ophthalmol 1999;117:1329-45.
14. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198-207.
15. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131: 541-60.
16. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 2000;20:325-30.
17. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351: 2805-16.
18. Spaide RE, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-4.
19. Lanchoney DM, Maguire MG, Fine SL. A model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1998;116:1045-52.
20. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
21. Bressler NM, Bressler SB, Congdon NG, Ferris FL 3rd, Friedman DS, Klein R, et al; Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-4.
22. Smiddy WE, Fine SL. Prognosis of patients with bilateral macular drusen. Ophthalmology 1984;91:271-7.
23. Bressler SB, Maguire MG, Bressler NM, Fine SL; the Macular Photocoagulation Study Group. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch Ophthalmol 1990;108:1442-7.
24. Klein R, Klein BEK, Jensen SC, Mener SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997;104:7-21.
25. Holz FG, Wolfensberger TJ, Piguet B, Gross-Jendroska M, Wells JA, Minassian DC, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 1994;101:1522-8.
26. Gass JDM. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol 1973;90:207-17.
27. Strahlman ER, Fine SL, Hillis A. The second eye of patients with senile macular degeneration. Arch Ophthalmol 1983; 101:1191-3.
28. Baun O, Vinding T, Krogh E. Natural course in fellow eyes of patients with unilateral age-related exudative maculopathy: a fluorescein angiographic 4-year follow-up of 45 patients. Acta Ophthalmol 1993;71:398-401.
29. Gass JDM. Photocoagulation of macular lesions. Trans Am Acad Ophthalmol Otolaryngol 1971;75:580-608.
30. Cleasby G, Nakanishi AS, Norris JL. Prophylactic photocoagulation of the fellow eye in exudative senile maculopathy. Mod Probl Ophthalmol 1979;20:141-7.
31. Wetzig PC. Treatment of drusen-related aging macular degeneration by photocoagulation. Trans Am Ophthalmol Soc 1988;86:276-90.
32. Wetzig PC. Photocoagulation of drusen-related macular degeneration: a long-term outcome. Trans Am Ophthalmol Soc 1994;92:299-306.
33. Sigelman J. Foveal drusen resorption one year after perifoveal laser photocoagulation. Ophthalmology 1991;98:1379-83.
34. Hyver SW, Schatz H, McDonald HR, Johnson RN. A case of visual acuity loss following laser photocoagulation for macular drusen. Arch Ophthalmol 1997;115:554-5.
35. Duvall J, Tso M. Cellular mechanism of resolution of drusen after photocoagulation. Arch Ophthalmol 1985;103:695-703.
36. Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch's membrane: a histochemical and morphologic study. Ophthalmology 1990;97:171-8.
37. Little HL, Showman JM, Brown BW. A pilot randomized controlled study of the effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology 1997;104: 623-31.
38. Figueroa MS, Regueras A, Bertrand J. Laser photocoagulation for macular soft drusen. Retina 1997;17:385-9.
39. Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. Br J Ophthalmol 1998;82:1169-74.
40. Bressler NM, Munoz B, Maguire MG, Vitale SE, Schein OD, Taylor HR, et al. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities: Waterman study. Arch Ophthalmol 1995;113:301-8.
41. Javornik N, Hiner CJ, Marsh MJ, Maguire MG, Bressler NM; for the Macular Photocoagulation Study Group. Changes in drusen and RPE abnormalities in age-related macular degeneration [abstract]. Invest Ophthalmol Vis Sci 1992;33:1230.
42. Ho AC, Javornik N, Maguire MG, Fine SL; Choroidal Neovascularization Prevention Trial Study Group. The Choroidal Neovascularization Prevention Trial (CNVPT): assessment of macular risk factors for CNV through 1 year [abstract]. Invest Ophthalmol Vis Sci 1997;38:S17.
43. Glaser BM, Campochiaro PA, Davis JL Jr, Sato M. Retinal pigment epithelial cells release an inhibitor of neovascularization. Arch Ophthalmol 1985;103:1870-5.
44. Patz A. Discussion. Trans Am Ophthalmol Soc 1988;92:289.
45. Discussion of: Wetzig PC. Treatment of drusen-related aging macular degeneration by photocoagulation. Trans Am Ophthalmol Soc 1988;86:276-90.
46. Matsumoto M, Yoshimura N, Honda Y. Increased production of transforming growth factor-beta 2 from cultured human retinal pigment epithelial cells by photocoagulation. Invest Ophthalmol Vis Sci 1994;35:4245-52.
47. Yoshimura N, Matsumoto M, Shimizu H, Mandai M, Hata Y, Ishibashi T. Photocoagulated human retinal pigment epithelial cells produce an inhibitor of vascular endothelial cell proliferation. Invest Ophthalmol Vis Sci 1995;36: 1686-91.
48. Sarks SH, Arnold JJ, Sarks JP, Gilles MC, Walter CJ. Prophylactic perifoveal laser treatment of soft drusen. Aust N Z J Ophthalmol 1996;24:15-26.
49. Guymer RH, Gross-Jendroska M, Owens SL, Bird AC, Fitzke FW. Laser treatment in subjects with high-risk clinical features of age-related macular degeneration. Posterior pole appearance and retinal function. Arch Ophthalmol 1997;115: 595-603.
50. Steinmetz RL, Haimovici R, Jubb C, Fitzke FW, Bird AC. Symptomatic abnormalities of dark adaptation in patients with age-related Bruch's membrane change. Br J Ophthalmol 1993;77:549-54.
51. Chen JC, Fitzke FW, Pauleikhoff D, Bird AC. Functional loss in age-related Bruchs membrane change with choroidal perfusion defect. Invest Ophthalmol Vis Sci 1992;33:334-40.
52. Ruiz-Moreno J, De La Vega C, Zarbin MA. Macular atrophy after photocoagulation of soft drusen. Retina 2003;23: 315-21.
53. Frennesson CI, Nilsson SEG. Significant decrease in exudative complications after prophylactic laser treatment of soft drusen maculopathy in a randomized study [abstract]. Invest Ophthalmol Vis Sci 1997;38(4 Suppl):18.
54. Frennesson CI, Nilsson SE. Effects of argon (green) laser treatment of soft drusen in early age-related maculopathy: a 6-month prospective study. Br J Ophthalmol 1995;79:905-19.
55. Frennesson CI. Prophylactic laser treatment in early age-related maculopathy: an 8-year follow-up in a randomized pilot study shows a reduced incidence of exudative complications. Acta Ophthalmol Scand 2003;81:449-54.
56. Olk RJ, Friberg TR, Stickney KL, Akduman L, Wong KL, Chen MC, et al. Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology 1999;106:2082-90.
57. Scorolli L, Corazza D, Morara M, Vismara S, Lugaresi ML, Meduri RA. Argon laser vs. subthreshold infrared (810-nm) diode laser macular grid photocoagulation in nonexudative age-related macular degeneration. Can J Ophthalmol 2003; 38:489-95.
58. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Ophthalmology 1998;105:11-23.
59. The Choroidal Neovastularization Prevention Trial Research Group. Choroidal neovascularization in the Choroidal Neovascularization Prevention Trial. Ophthalmology 1998;105: 1364-72.
60. Ho AC, Maguire MG, Yoken J, Lee MS, Shin DS, Javornik NB, et al. Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1999;106:1367-73.
61. Kaiser RS, Berger JW, Maguire MG, Ho AC, Javornik NB; Choroidal Neovascularization Prevention Trial Study Group. Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study. Arch Ophthalmol 2001;119:826-32.
62. Choroidal Neovascularization Prevent ion Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology 2003;110:971-8.
63. Owens SL, Guymer RH, Gross-Jendroska M, Bird AC. Fluorescein angiographic abnormalities after prophylactic macular photocoagulation for high-risk age-related maculopathy. Am J Ophthalmol 1999;127:681-7.
64. Owens SL, Bunce C, Brannon AJ, Wormald R, Bird AC; Drusen Laser Study Group. Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: results of an interim analysis. Eye 2003;17:623-7.
65. Rodanant N, Friberg TR, Cheng L, Aurora A, Bartsch D, Toyoguchi M, et al. Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration. Am J Ophthalmol 2002;134:577-85.
66. Friberg TR, Musch D. Prophylactic Treatment of Age-Related Macular Degeneration (PTAMD): update on the clinical trial [abstract]. Invest Ophthalmol Vis Sci 2002;43:e-abstract 2904.
67. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials 2004;1: 91-107.
68. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. Baseline characteristics, the 25-item National Eye Institute visual functioning questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 2004;111:1307-16.